Seven Interdisciplinary Companies Secure Fresh Funding in FreeS Family News Vol.22
Neurodome
Neurodome, Inc.
methuselah
Medical Nutrition Product R&D, Production, and Sales
「FreeS Family Financing News" will不定期发布Fengrui投资的企业的融资新闻。除了我们New InvestmentThe companies that Frees Fund has invested inFollow-up FinancingIt is also covered. Together, we witness every step of innovative companies from 0-1, from 1-10, and then from 10-100.
In this issue, at a glance:
Technology + Healthcare: Frees Fund Angel Round ProjectTsingPAITens of millions of yuanPre-A round financing,FengruiContinuous Injection; Fengrui Capital Angel Round ProjectNeurodome MedicalCompleted tens of millions of yuanSeries A Financing。
Consumption + Healthcare: Frees Fund A Round ProjectmethuselahNearly 200 Million Yuan CompletedSeries B Financing, NeurodomeContinuous Investment。
Embodied Intelligence: Frees Fund Angel Round ProjectZhuji DynamicsCompletedSeries A+ Financing，Cumulative completion in half a year$50 Million Series A Round Financing, PeakFitContinuous Injection。
Biomanufacturing：FREES FUND Angel Round ProjectBeijing Yanwei Technology Co., Ltd.Completed a new round of financing.
Advanced Manufacturing: Frees Fund Angel Round ProjectOptiFutureComplete tens of millionsSeries A+ Financing, PeakwayContinuous Injection; Peak Capital Angel Round ProjectChu Guang 3DTens of Millions of YuanAngel+ Round Financing, NeurodomeContinuous Injection。
(The financing information summarized in this article is limited to that publicly disclosed from February to March 2025, sorted by the publication date of corporate financing news.)
FREES FUNDAngel Round Project TsingPAIAnnouncement CompletedTens of millions of yuan in Pre-A round financing. The investors in this round include Gao Tejia Investment, Chengmei Capital, and Xiamen High-Tech Investment.Existing shareholder Frees Fund continues to increase its investment.。
/ Words from the Investor /
Biomedical ImagingEquipment has been continuously evolving towards higher dimensions, such as from two-dimensional to three-dimensional, from structure to function, and from single spectrum to hyperspectral. Photoacoustic imaging technology combines the characteristics of optical and ultrasound imaging, featuring high-precision 3D imaging, functional imaging, molecular imaging, and non-invasive properties. It provides a new perspective for in vivo imaging and offers clinicians richer image information of biological tissues, aligning withPrecision MedicineAnd the general trend of biomedical imaging equipment development.
TsingPAI starts from the first principle, withAlgorithm InnovationAt its core, it has the strength of independent research and development in core hardware, as well as closely collaborated clinical resources. We have observed that TsingPAI's commercialization strategy is clear and traceable, making it an excellent and pragmatic entrepreneurial team. We look forward to TsingPAI leading the development in the field of photoacoustic imaging.
/ Company Details /
TsingPAI is a professionalPhotoacoustic Imaging Technology Team, focusing on the innovative technology research and development, sales, scientific research, and clinical application promotion of photoacoustic imaging systems and their core component products.
The team provides scientists and clinical experts with high-quality photoacoustic bioimaging technology products and technical services, supporting cutting-edge research in life sciences, pharmaceuticals, and medicine.
The company currently has the Marsonics PIIP Photoacoustic Integrated Imaging Platform (2D tomography, 3D tomographic synthesis imaging), PIIP3D Photoacoustic 3D Imaging System (isotropic high-resolution 3D non-real-time imaging), CPIIP Photoacoustic Clinical Integrated Imaging Test System (mainly for clinical trials). The RT-PIIP3D 3D real-time photoacoustic imaging system is scheduled to be launched in 2025.（Report details: 【ZGC Zhiyou Research Institute】TsingPAI Completes Pre-A Round Financing of Tens of Millions of Yuan, Promoting Productization of Photoacoustic Clinical Imaging System）
FREES FUND Series A Project MethuselahAnnouncement CompletedNearly 200 Million Yuan in Series B FinancingThis round of financing was jointly led by the fund under CICC Capital, Hongsheng Capital, and Honghui Fund, with participation from Fengqiao Capital.FREES FUND Follow-up Investment。
/ Investor Says /
As Methuselah'sThe first round of institutional investors,Since the beginning of Methuselah's financing, FreeS Fund has been deeply involved in its strategic development and has now completed the third round of additional investment. Methuselah is very forward-looking in its corporate strategy layout, and we remain firmly optimistic about its future.China Medical Nutrition IndustryLong-term development prospects.
Methuselah is one of the few in China to achieveMedical Food、Low GI FoodsAndEnergy-Control FoodsThree Major Product Lines for Synergistic DevelopmentMedical Nutrition EnterpriseWe are optimistic about the future growth potential of Methuselah. Relying on Frees Fund's years of accumulated industry-academia resources in the biopharmaceutical field, we will continue to support Methuselah in expanding its market presence and accelerating the advancement of China's medical nutrition industry into a higher-quality development phase.
/ Company Details /
Methuselah is a large-scale company integrating research and development, production, and sales.Medical Nutrition Technology EnterpriseThe company has formed a strategic alliance with large medical food technology enterprises in the United States, and collaborated with multiple clinical nutrition expert teams in China to develop a series of medical nutrition products that meet the characteristics of the Chinese population, adhering to...Different Populations, Different NutritionThe concept.
Under its umbrella "DGI"And"Energy Control"The two major series focus on the research, production, and sales of low glycemic foods and medical nutrition weight-loss foods, covering up to hundreds of SKUs. With excellent quality, outstanding taste, and precise market positioning, the company’s products have successfully entered several well-known large supermarkets such as Sam's Club, Costco, and Bailian, reaching a vast number of consumers."(For details, see [Arterial Network] Methuselah, a leading company in medical nutrition, completes a new round of nearly 200 million yuan in financing)
FRE Angel Round Project: Neurodome, Inc.CompletedTens of Millions of Yuan in Series A FinancingThis round of financing was led by Huafang Capital and iFlytek Ventures, with Heping Capital participating.
/ Investors Say /
In the field of brain science, research on the mechanisms of the human brain and the development of neuromodulation technologies have provided possibilities for regulating brain activity through physical fields and intervening in brain diseases.Neuromodulation TechnologyTo date, it has developedNearly 60 years,However, at the same timeNon-invasive, Deep Brain, PreciseNeuromodulation technology is still scarce.
Neurodome StandingTime Interference Technology(Temporal Interference, abbreviated as TI), developed a series of electrical stimulation, ultrasound stimulation, and magnetic stimulationNeurostimulation Products, forClinical Research and Treatment of Brain DiseasesNew tools have been provided, achieving industry-leading clinical progress across various indications. Peakview Capital is optimistic about Neurodome's efficient and solid completion of the clinical validation of TI technology, offering an innovative solution originating from China for the treatment of brain diseases.
/ Company Details /
The field of brain science has a huge potential for therapeutic demand. The number of patients with various brain diseases in China is close to 130 million, including more than 50 million patients with depression. The burden caused by brain diseases accounts for 23% of the total disease burden.
In the field of brain science, Neurodome, Inc. has been deeply engaged.Non-invasive NeuromodulationIn the field for nearly 10 years, continuously refining TI technology, and being the first to master and achieve precise non-invasive deep brain neuromodulation in humans using TI.
Neurodome, Inc.TI Products, canAccurately Output Stimulation Signals in Different Modes, fine-tune parameters according to clinical needs to achieve non-invasive, deep-brain, high-precision, multi-target central nervous system stimulation and intervention, which canWidely used in the treatment of various neurological/psychiatric disorders。(For details, see [VcBeat] TI Global Leader Neurodome Completes Series A Financing, Breaking New Ground in Non-Invasive Deep Brain Neuromodulation)
FREES FUND Angel Round Project: Zhuji PowerAnnouncement CompletedSeries A+ Financing, with a total of 500 million yuan in Series A round financing completed over the past six months. It has received strategic support from top institutions in both industrial and financial aspects. Multiple existing shareholders have continued to invest, including strategic industry investors such as Alibaba Group, China Merchants Venture Capital, Shangqi Capital, NIO Capital, Legend Capital, Beyond Era, and Nice Group. Renowned financial investors include HighFort Venture Capital, Oase Capital, and Ming Shi Venture Capital.FREES FUND, Nanshan Zhanxin Investment.
/ Investor Says /
In the field of embodied intelligence and humanoid robotics, the industry is transitioning from the critical technology research phase to a new stage of productization and commercialization.Hardware Design and Manufacturing of the Robot Body、Development of Embodied Brain Systems, andCerebellum Whole-Body Control Technology Driven by Reinforcement LearningThese three core elements work together, continuously iterating, jointly forming a technological flywheel that propels the industry forward, and becoming the key driving force for the productization and commercialization of robots.
After years of in-depth development, ZhiJi Dynamics has successfully built a range of high-performance robots covering all sizes andMulti-form Biped Robot TRON 1The hardware product system, while continuously promotingVGM (VideoGenMotion) Embodied Operation AlgorithmAndAgent Development Toolchaindevelopment and refinement. We believe that, with solid technical accumulation and product layout, Neurodome will empower downstream industries, providing practical assistance to humans in completing various industrial and service tasks across diverse scenarios, and launch products with significant commercial value.Agent-level robotic products, helping the industry achieve leapfrog development.
/ Company Details /
Zhuji Dynamics was founded in 2022, focusing on three core areas.Embodied Intelligence Technology, namely the design and manufacturing of the main body hardware, cerebellum-based whole-body motion control through reinforcement learning, and the training strategy for the embodied brain model, focusing onFull-size General-purpose Humanoid Robot, and derivedBipedal RobotAnd other products.
With fully self-developed core software and hardware technologies, combined with humanoid foundational models, Zhuzhi Dynamics provides solutions based on its general mobile operation platform and embodied intelligence software tools to enterprise customers, system integrators, and individual developers across various fields.Humanoid Robot Hardware and Software SystemAndEmbodied Agent Development Toolchain, promoting the widespread application of embodied intelligence in fields such as scientific research, manufacturing, commerce, and households.
Among these, Zhujidongli has recently made a series of key advancements in the fields of AI exploration, algorithm development, and hardware design and manufacturing for robots.(For details, see [36Kr Pro])Completed 500 Million Yuan in Financing Within Half a Year, Alibaba, NIO, Lenovo, and Others Invested in Humanoid Robots）
FREES FUNDAngel Round Project: Beijing Yanwei Technology Co., Ltd.Received investment from SDIC Chuangyi and completed a new round of financing.
/ Investors Say /
Congratulations to Beijing Yanwei Technology Co., Ltd. on completing a new round of financing and gaining the support of the national team. Frees Fund was the lead investor in Yanwei's angel round and has continued to increase its support in subsequent rounds of financing. In the early stages of investment, we were optimistic about Yanwei's...Two chassis cell platforms supported by Rhodococcus and Bacillus, and its deep technical accumulation.
After three years of development, Beijing Yanwei Technology Co., Ltd. has lived up to expectations and developedLipid Biostimulants and Their Derived Molecules, and developed a variety of Rhodococcus catalysts. The company has also achievedTen-thousand-ton level production capacity, proactively layout R&D platforms, expand talent teams, and ultimately achieved significant commercial monetization. Congratulations again, and we look forward to Yanwei becoming a leader in China's biomanufacturing field.
/ Company Details /
Beijing Yanwei Technology Co., Ltd. was founded in 2022, focusing on the two core chassis cells of Rhodococcus and Bacillus.Cell CatalystAndBiosurfactantsThe biomanufacturing and application development, with downstream applications covering oilfield chemicals, agri-food, daily chemical cosmeceuticals, and other fields.
The Bacillus Lipid Biostimulant developed by Beijing Yanwei Technology Co., Ltd. is globallyFirst CommercializationA brand-new product that can significantly promote fertilizer absorption, regulate plant metabolism and physiological status, improve soil microbial structure and fertility, and enhance crop resistance. It has achieved significant yield increase and quality improvement on over 70 crops across 25 regions in China, demonstrating its effectiveness.Low concentration, wide applicability, high cost-effectiveness, easy applicationThe advantage.(ReportFor more details, see [Synthetic Biology Network] SDIC Re-enters Synthetic Biology, Beijing Yanwei Technology Co., Ltd. Secures New Funding! World's First Commercialization of Synthetic Biology New Product!
FREES FUND Angel Round Project: Youjie FutureAnnouncement of Continuous CompletionSeries A and Series A+ Equity Financing, with tens of millions of yuan raised in this round of financing. The A-round financing was led by the Rainforest Fund under Zhongguan Village Development Group, with participation from existing shareholders.FREES FUND Follow-up Investment, A+ round was exclusively invested by He Shi Family Capital.
/ Investors Say /
Neurodome leverages interdisciplinary innovative capabilities toDeep Integration of AI Generative Design Algorithms with Simulation Physical Models, solving the deterministic design challenges in complex industrial scenarios. Frees Fund has invested in Youjie Future for three consecutive rounds since 2021.
We have witnessed the OptFuture software launched by Youjie Future grow from scratch, gradually completing a hundred benchmark cases. This marksGenerative technology has moved from the "concept validation" stage to the "large-scale implementation" stage., while also showcasing the innovative potential of domestically produced industrial software. We look forward to Youjie's future contributions in continuing to drive the intelligent design ecosystem and assisting China's high-end manufacturing to advance towards the top of the value chain.
/ Company Details /
Neurodome Positions Itself as "The New Generation of Generative Design Industrial Software," Independently Developed in ChinaNext-Generation Intelligent Design Topology Optimization SaaS PlatformA high-tech company that has been established for four years achieved nearly 30 million RMB in business contracts in 2024. Its clients include leading companies such as China North Industries Group, China Aerospace Science and Industry Corporation, Jiuzhou Yunjian, Meituan Drones, and Volkswagen, with initial success in commercial expansion.
The products of this startup are gradually replacing the formerly dominant overseas industrial design giants in China, making waves in the military, aerospace, and new energy vehicle sectors.Efficiency Revolution。(For details, see [VentureBeat] Henan Post-90s Academic Achiever Creates "Industrial Version of DeepSeek," Generates Tens of Millions in Annual Revenue, Military and Aerospace Companies Are Rushing to Use It)
FREES FUND Angel Round Project: TsingPAIAnnounced the completion of an angel+ round of financing worth tens of millions of yuan. This round was led by Oriza Ventures, with joint investments from Optics Valley Industrial Investment and Changshu Guofa Venture Capital. Existing shareholders...FREES FUND Additional Investment。
/ Investors Say /
With the rapid development of related industries driven by advanced manufacturing capabilities and their applications, the demand for high-precision imaging, especially micro-nano three-dimensional imaging, will increase rapidly.
The Chuguang team, relying on years of industry experience and scientific research accumulation,Spectral Confocal，Encoded ImagingBased on technical achievements, we are able to quickly provide solutions for high-speed, high-precision measurement of micro-nano 3D structures. We look forward to becoming a leading precision measurement platform enterprise under the wave of related industrial upgrading and advanced manufacturing.
/ Company Details /
Chuguang 3D, a manufacturer of precision optical inspection instruments, was founded in 2022 and focuses onOptical 3D Imaging with Micro-Nano Scale PrecisionAndNew Measurement and Detection TechnologiesResearch, dedicated to building a new generation of 3D imaging technology platform, becoming a global leading provider of optical micro-nano 3D perception and measurement inspection solutions.
Chuguang 3D ReleasedRevolutionary 3D Microscopic Imaging Products —— Surface Confocal 3D Microscope Sensor, Surface Confocal 3D Microscope/ProfilometerThe product adopts a brand-new technical approach, based on the principle of wide-field microscopic imaging. It uses structured light illumination to modulate the surface information of the object being measured, eliminates out-of-focus signal interference, and obtains the 3D topography of the microscopic surface through vertical axial scanning. At the same time,Applicable to complex feature surfaces(such as scattering surfaces) andSmooth Surface, and the Z-axis accuracy can be flexibly adjusted within the range of 1nm to 1μm according to the application scenarios.(For details, see [Hard Kr] Relying on the HUST Technical Team, Wuhan High-End Equipment Company Secures Tens of Millions in Financing)
